Association of the pathophysiology of chronic cough refractory to specific treatments with levels of hydrogen sulfide(H2S) in serum and sputum supernatant

Association of the pathophysiology of chronic cough refractory to specific treatments with levels of hydrogen sulfide(H2S) in serum and sputum supernatant - Association of the pathophysiology of chronic cough refractory to specific treatments with levels of hydrogen sulfide(H2S) in serum and sputum supernatant

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000019350

Enrollment

120

Registered

2015-10-14

Start date

2015-10-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic cough

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Group(a) Patients with asthmatic cough lasting for 8 weeks or more despite receving adequate therapies Group(b) Patients with asthmatic cough whose cough is well-controlled Group(c) Patients with non-asthmatic cough lasting for 8 weeks or more despite receving specific therapies Group(d) Controll subjects

Exclusion criteria

Exclusion criteria: If patients meet the following criteria, they are excluded. Patients who have other respiratory disease such as tuberculosis and lung cancer currently smoke, had smoking history with 10 pack-years or more, or had quitted smoking within 6 months prior to the enrollment

Design outcomes

Primary

Measure	Time frame
Elevated levels of H2S would associate with the pathophysiology of chronic cough refractory to specific treatments	—

Countries

Japan

Contacts

Public ContactKensuke Fukumitsu

Nagoya City University Dept of Respiratory Medicine, Allergy and Clinical Immunology

k-fkmt@med.nagoya-cu.ac.jp052-853-8216

Outcome results